Australia's most trusted
source of pharma news
Posted 7 February 2024 PM
New Zealand company AFT Pharmaceuticals has announced the launch of the first patented, New Zealand-developed medicine with clinical studies in the United States.
The pharma's intravenous opioid-free pain relief, Maxigesic IV, is marketed by licensee Hikma Pharmaceuticals in the US under the brand name Combogesic IV.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.